

Supplementary Information

Daily Cases in Saudi Arabia	2
Polymorphisms	2
Ct values	3
Table S2. Cities providing samples	5
Table S3. Comorbidities	6
Table S4. Detected indels	7
Table S5. Nucleocapsid N (control and mutant) interacting partners with no significant change in interaction.....	10
Table S6. Proteins displaying significant differential interactions.....	13
Table S7. Phosphorylation.....	16
Table S8. Differentially expressed genes	17
Table S9. Primers	21
References	22

Daily Cases in Saudi Arabia

The numbers of Covid-19 cases registered in Saudi Arabian Cities were collected from The Ministry of Health Command Centre for COVID-19 (<https://covid19.moh.gov.sa>), Saudi Center of Disease Control and Prevention (<https://covid19.cdc.gov.sa>), the Saudi Press Agency (SPA) (<https://www.spa.gov.sa/search.php?lang=en&search=COVID>), The Saudi Ministry of Interior (<https://www.moi.gov.sa/>), and Algaissi *et al.*¹.

Polymorphisms

Duplicate reads were removed from the mapped short Illumina sequence reads using picard tools' MarkDuplicates function (Broad Institute, GitHub repository. <http://broadinstitute.github.io/picard/>). Apparent mismatches were collected from the output of samtools mpileup². Distal read positions were excluded and only read mapping and base calling qualities of at least 30 were considered. Positions with at a minimum coverage of 1000 and with an overall mismatch rate between 0.3 and 0.7 were considered as potential within-host polymorphic sites.

For each hospital, the number of samples with detected polymorphism at a given SNP site was plotted against the number of samples from the hospital that had this SNP in the assembled genome and the correlation was calculated. Examples of such plots for six

different SNPs are shown in [Figure S9](#).

We considered the frequency of a given SNP in the assembled virus genomes from a hospital as a proxy for the prevalence of this virus variant at the hospital. We further consider the probability of seeing polymorphisms of a given SNP due to co-infection as a product of the frequency of viruses with that SNP circulating among patients (the more prevalent a virus strain is in a given hospital environment the more likely it is to co-infect other COVID19 patients). Therefore, if observed polymorphisms were the result of co-infections we would expect to see a positive correlation between SNP polymorphisms and SNP frequencies at different hospitals. In contrast, if observed polymorphisms were the result of inter-sample contaminations, such a correlation is not expected, as contamination would solely rely on the order and workflow by which the samples were handled.

The observed positive correlation between SNP polymorphisms and SNPs in assembled genomes between hospitals ([Figure S9](#)) is therefore consistent with the observed polymorphisms being the result of co-infection of patients. And we similarly consider this to be the case for the R203K/G204R SNPs.

Ct values

Although not associated with severity of infection, significantly lower Ct values have

been reported for the D614G SNP³⁻⁵. In our experimental setup, samples were not only

selected for further processing based on the initially obtained Ct values, but sample

qPCRs were also run in separate batches, which produced separate standard curves.

Additionally, two different laboratory kits were used for the qPCRs (see [Methods](#)).

Furthermore, viral loads will also be a function of sampling time, with fluctuations over

the course of infection and potential recovery. With these caveats in mind, we

nevertheless tested for differences in Ct values between samples. This was done using

samples processed with the TaqPath kit (see [Methods](#)). Hence, to prove that that the

R203K/G204R SNPs result in higher viral loads, experimental *in vitro* infection studies

with different virus genotypes are needed.

Table S2. Cities providing samples

City	Hospital	Total samples	Samples with patient outcome information	Deceased patients	Samples with R203K/G204R SNPs	R203K/G204R frequency
Madinah	General	42	37	7	2	0.0476
	King Fahad Medical	16	14	6	0	0
	Madinah Children Hospital	3	3	0	0	0
	Ohoud	251	238	63	8	0.0319
Makkah	Al Zahir	16	16	3	3	0.1875
	Al Noor	71	69	0	0	0
	Quarantine Hotel	144	144	0	4	0.0278
Jeddah	King Abdullah Medical Complex	262	262	105	101	0.3855
Riyadh	Sulaiman Al Habib	69	53	15	6	0.0870
Eastern Region	Sulaiman Al Habib, Eastern	18	14	0	0	0
TOTAL		892	850	199	124	0.1390

Table S3. Comorbidities

	Patients	Incidence	Mortality	Incidences reported in other studies ⁶⁻¹²
Diabetes	272	0.39	0.34	0.074-0.431
Hypertension	238	0.35	0.35	0.095-0.375
Cardiovascular	76	0.11	0.45	
Lung BA	44	0.06	0.23	
Kidney CDK	24	0.03	0.49	0.05-0.189
Cerebrovascular	10	0.01	0.40	
Any comorbidity	386	0.56	0.32	
No comorbidity	303	0.44	0.24	

Notes: 203 patients have no available data on comorbidity, and these are not included in the incidence calculations. Only samples with available patient outcome information (850 samples) are included in the mortality calculations.

Table S4. Detected indels

position	type	length	ref	allele	sample count
103	del	2	CTG	C	2
509	del	9	GGTCATGTTA	G	1
668	del	3	AGTT	A	3
685	del	9	AAAGTCATTT	A	4
898	ins	262	TTCATGCACTTGTCCGAACAACACTGGACT TTATTGACACTAAGAGGGGTGTATACTGC TGCCGTGAAC	TTCATGCACTTGTCCGAACAACACTGGACTTT ATTGACACTAAGAGGGGTGTATACTGCTGCC GTGAACCACCTTTCTTGCACTTACTTTTTA TAGGAACCTCCTGTCACTCACTCTCACACAC ACACTTAGATGAACCTGATGGCTACCCCTTT GAGTGCATTAAGACCTCTAGCACGTGCTG GTAAGCCTCATGCACTTGTCCGAACAAC GGACTTTATTGACACTAAGAGGGGTGTATAC TGCTGCCGTGAAC	1
2463	del	4	TAAAAA	TAA	1
2628	del	3	TTAT	TT	1
2882	ins	282	TGTGTTGTGGCAGATGCTGTC	TGTGTTGTGGCAGATGCTGTCGTGTTGTGGC AGATGCTGTCGTGTTGTGGCAGATGCTGTCG TGTTGTGGCAGATGCTGTCGTGTTGTGGCAG AGGCTGCTCGTGTGTCAGATGCTGTCG TGTTGTGGCAGATGCTGTCGTGTTGTGGCAG ATGCTGTAGTGTGCATCAGAGGCTGCTCGT GTTGTGGCAGATGCTGTCGTGTTGTGGCAG ATGCTGTCGTGTTGTGGCAGATGCTGTCG TTGTGGCAGATGCTGTCGTGTTGTGGCAGAT GCTGTC	1
2882	ins	141	TGTGTTGTGGCAGATGCTGTC	TGTGTTGTGGCAGATGCTGTCGTGTTGTGGC	1

				AGATGCTGTCGTGGCAGATGCTGTCG TGTTGTCGTGGCAGATGCTGTCGTGGCAG ATGCTGTCGTGGCATCAGAGGCTGCTCGT GTTGTCGTGGCAGATGCTGTC	
7626	ins	49	ATTGTGATAACATTCTGTGCTGGTAGT	ATTGTGATAACATTCTGTGCTGGTAGTTGTGA TACATTCTGTGCTGGTAGT	2
10535	del	27	TACATGCACCATAATGGAATTACCAACTG	T	1
11074	ins	11	CTTTTTTTT	CTTTTTTTTTT	1
18896	ins	309	TTGTTAACCGTGTGACTGGACTATTGAAT ATCCTATAATTGGTGTAACTGAAGATTAA ATGCCGCTTGTAGAAAGGTTCAACA	TTGTTAACCGTGTGACTGGACTATTAATAT CCTATAATTGGTGTAACTGAAGATTAAATG CGGCTTGTAGAAAGGTTCAACATAACATGTT GTGCCAACCAACCAGCACTCCTGGGACCTCC ACAGTGCACCTGGCACCTCTGGGACTCCAT CCTCCCTGCCTGCCACACAGCCCCGTCC CTCTCTGTAACTTCAACCTCAACTTAC AGATGGGAATGTTAACCGTGTGACTGGACT ATTGAATATCCTATAATTGGTGTAACTGAA GATTAATGCCGCTTGTAGAAAGGTTCAACA	1
19517	del	3	TGTA	T	1
21066	del	5	TAAAAA	TAA	1
21561	del	2	CAA	CA	2
21624	del	33	GAACTCATTACCCCTGCATACACTAATT CTTT	G	1
21740	del	45	TCCAATGTTACTGGTCCATGCTATACT GTCTCTGGGACCAATG	TCCAATG	1
21781	ins	3	CAA	CAAA	1
21990	del	6	TTTATTAA	TTTA	3
22048	del	3	TGCG	T	1
22288	del	6	TGCTTTA	T	1
22353	del	7	CTTATTAT	CTTAT	1

23701	del	1	CA	C	1
27263	del	29	CTTTAAAGTTCCATTTGGAATCTTGATT	CTT	1
27694	del	8	TTTCTTATT	TTT	1
27697	del	5	CTTATT	CTT	4
28949	del	11	AGATTGAACCAAG	A	1
29727	del	22	TTTCACCGAGGCCACGCAGGAGTA	T	1
29755	del	1	GA	G	2
29774	del	18	CTAGGGAGAGCTGCCTATA	CTA	3
29865	ins	5	AA	AAAACA	1
29865	ins	7	AA	AAACAACA	4
29865	ins	3	AA	AACA	1
29865	ins	9	AA	AACCACAACA	1
29865	ins	10	AA	AAGCCACAACA	1
29866	ins	3	A	AACC	1
29866	ins	6	A	AAGATGC	1
29866	ins	9	A	AAGCAGCCTC	1
29866	ins	3	A	AATG	1
29866	ins	8	A	AGCAGATGC	1

Table S5. Nucleocapsid N (control and mutant) interacting partners with no significant change in interaction

Gene Name	Protein IDs											
PRPF38B	Q5VTL8	CSNK2A1	P68400	GNB2L1	P63244	CARHSP1	Q9Y2V2	RAVER1	WZ13	RPS27	P42677	
PRPF38A	Q8NAV1	CSNK2A2	P19784	GNL3	Q9BVP2	LUC7L	Q9NQ29	RBM14	Q96PK6	RPS27A	P62979	
TMA7	Q9Y2S6	CSRP2	Q16527	GRWD1	Q9BQ67	LUC7L2	Q9Y383	RBM17	Q96I25	RPS28	P62857	
TBL2	Q9Y4P3	PRPF40A	O75400	GSK3B	P49841	LUC7L3	O95232	RBM28	3	RPS29	P62273	
ARL6IP4	Q66PJ3	FAM32A	Q9Y421	EMD	P50402	PFN1	P07737	RCC2	Q9P258	RPS3	P23396	
ATXN2L	Q8WWM7	IBA57	Q5T440	GTPBP4	Q9BZE4	FXR1	P51114	RBM39	Q14498	RPS3A	P61247	
BAG2	O95816	PES1	O00541	GNL2	Q13823	FXR2	P51116	RP9	Q8TA86	RPS4X	P62701	
UQCRC2	P22695	RPA3	P35244	HADHA	P40939	PDCD11	Q14690	RPL10	P27635	RPS5	P46782	
BCLAF1	Q9NYF8	SNIP1	Q8TAD8	GRN	P28799	MAT2A	P31153	RPL10A	P62906	RPS6	P62753	
FTSJ3	Q8IY81	DDX18	Q9NVP1	CDKN2A	Q9NXV6	MATR3	P43243	RPL11	P62913	RPS7	P62081	
ARGLU1	Q9NWB6	DDX21	Q9NR30	KTN1	Q86UP2	MAZ	P56270	RPL12	P30050	RPS8	P62241	
STAU1	Q5JW28	DDX46	89	PPP1CB	P62140	ZCCHC17	Q9NP64	RPL13	P26373	RPS9	P46781	
AIP	O00170	DDX47	Q9H0S4	HLA-C	P10321	MFAP1	P55081	RPL14	P50914	RPSA	P08865	
BRIX1	Q8TDN6	DDX5	P17844	HMGB1	P09429	MKI67	P46013	RPL15	P61313	RRP12	Q5JTH9	
NTPCR	Q9BSD7	DDX56	Q9NY93	HMGB2	P26583	PRPF19	4	RPL18	Q07020	RRP15	Q9Y3B9	
BYSL	Q13895	DEK	P35659	PHF5A	Q7RTV0	CWC25	Q9NXE8	RPL18A	Q02543	RRP1B	Q14684	
NOP16	Q9Y3C1	DHX15	O43143	TUBB8	7	MPG	P29372	RPL19	P84098	RRP9	O43818	
PIN1	Q13526	DHX30	Q7L2E3	HNRNPA0	Q13151	EFTUD2	Q15029	RPL21	P46778	RRS1	Q15050	
CACYBP	Q9HB71	DHX9	Q08211	HNRNPA2	B1	P22626	PRPF8	Q6P2Q9	RPL22	P35268	RSL1D1	O76021

					P51991-							
EIF5B	O60841	DDX6	P26196	HNRNPA3	2	ZMAT2	Q96NC0	RPL23	P62829	RSRC2	Q7L4I2	
TOP1	P11387	DKC1	O60832	HNRNPAB	Q99729	MRPL14	Q6P1L8	RPL23A	P62750	RTCB	Q9Y3I0	
CBR1	P16152	DDX1	Q92499	HNRNPC	G3V4C1	MRPS12	O15235	RPL24	P83731	RTTN	Q86VV8	
CBX3	Q13185	YTHDC2	Q9H6S0	HNRNPF	P52597	MRT04	Q9UKD2	RPL27	P61353	RUVBL1	Q9Y265	
CCDC12												
4	Q96CT7	ACACA	Q13085	HNRNPH1	P31943	MSN	P26038	RPL27A	P46776	RUVBL2	Q9Y230	
HNRNPA												
1	P09651	DUT	P33316	HNRNPK	P61978	MTHFD1	P11586	RPL28	P46779	SAE1	Q9UBE0	
CCT2	P78371	HMGA1	17096	HNRNPL	P14866	MYBBP1A	0	RPL29	P47914	SAFB	Q15424	
CCT3	P49368	C8orf33	Q9H7E9	HNRNPM	P52272	MYH9	P35579	RPL3	P39023	SEC61B	P60468	
CCT4	P50991	LSM14A	Q8ND56	HNRNPR	O43390	NCL	P19338	RPL30	P62888	SERBP1	Q8NC51	
CCT5	P48643	EBNA1BP2	Q99848	HNRNPU	Q00839	NAT10	Q9HOA0	RPL31	P62899	SET	Q01105	
CCT6A	P40227	EEF1G	P26641	HNRNPUL	1	Q9BUJ2	NHP2	Q9NX24	RPL32	P62910	SF1	Q15637
CCT7	Q99832	EEF2	P13639	HNRNPUL	Q1KMD							
CCT8	P50990	EIF1AX	P47813	HP1BP3	Q5SSJ5	NOC3L	2	RPL35	P42766	SF3B2	Q13435	
ATOX1	O00244	DDX54	Q8TDD1	SUPT16H	Q9Y5B9	NONO	Q15233	RPL35A	P18077	SF3B3	Q15393	
EIF3G	O75821	DDX52	Q9Y2R4	HSP90AA1	P07900	NOP2	P46087	RPL36	Q9Y3U8	SFPQ	P23246	
LTV1	Q96GA3	EIF3B	P55884	ILF2	Q12905	NOP56	O00567	RPL37A	P61513	SLC25A3	Q00325	
CFL1	P23528	DDX50	Q9BQ39	WDR1	Q9BV38	NOP58	Q9Y2X3	RPL38	P63173	SLC25A5	P05141	
TXNDC1												
2	O95881	EIF3D	O15371	HSPA4	P34932	NOSIP	Q9Y314	RPL4	P36578	SLC25A6	P12236	
CHERP	Q8IWX8	DDX24	Q9GZR7	HSPA4L	O95757	NPM1	P06748	RPL5	P46777	SNRNP2	Q8WVK	
SNRPD2	P62316	EIF4A1	P60842	HSPA5	P11021	NUMA1	Q14980	RPL6	Q02878	SNRPA1	P09661	
CHTOP	Q9Y3Y2	EIF4A3	P38919	HSPA6	P17066	PA2G4	Q9UQ80	RPL7	P18124	SNRPD3	P62318	

										SREK1IP	
CIAPIN1	Q6FI81	PABPN1	Q86U42	HSPA8	P11142	PARK7	Q99497	RPL7A	P62424	1	Q8N9Q2
PELO	Q9BRX2	FAHD1	Q6P587	HSPA9	P38646	PARP1	P09874	RPL8	P62917	SRP14	P37108
CSNK2B	P67870	EIF6	P56537	HSPD1	P10809	PCBP1	Q15365	RPL9	P32969	SRP19	P09132
CNBP	P62633	ENO1	P06733	HSPE1	P61604	PCBP2	Q15366	RPLP1	P05386	SRP68	Q9UHB9
CNN3	Q15417	SOD1	P00441	HSPH1	Q92598	PCCA	P05165	RPLP2	P05387	SRP9	P49458
SUGP2	Q8IX01	VIM	P08670	TPR	P12270	PCMT1	P22061	RPS11	P62280	SRRM2	Q9UQ35
MRPS22	P82650	ERH	P84090	PLRG1	O43660	PDAP1	Q13442	RPS12	P25398	SRSF1	Q07955
CPSF6	Q16630	EWSR1	Q01844	IGF2BP1	Q9NZI8	PHF6	Q8IWS0	RPS13	P62277	SRSF11	Q05519
MRPS26	Q9BYN8	EXOSC6	Q5RKV6	IGF2BP3	O00425	PHGDH	O43175	RPS14	P62263	SRSF3	P84103
TUBB	P07437	FASN	P49327	ILF3	Q12906	PIN4	Q9Y237	RPS15	P62841	SRSF4	Q08170
TUBB4B	P68371	FAU	P62861	DNAJC8	O75937	PLK1	P53350	RPS15A	P62244	SRSF5	Q13243
TXN	P10599	FBL	P22087	TMA16	Q96EY4	PLS3	P13797	RPS16	P62249	SRSF6	Q13247
U2AF2	P26368	RRP8	O43159	RBBP4	Q09028	POLR1C	O15160	RPS17	P08708	SRSF7	Q16629
U2SURP	O15042	FMR1	Q06787-7	POLR2E	P19388	PPIA	P62937	RPS18	P62269	SRSF9	Q13242
UBA52	P62987	FN3KRP	Q9HA64	KHSRP	Q92945	PPIB	P23284	RPS19	P39019	SSB	P05455
UPF1	Q92900	FRG1	Q14331	PWP1	Q13610	PPIL1	Q9Y3C6	RPS2	P15880	SUB1	P53999
VCP	P55072	FUBP1	Q96AE4	KPNA2	P52292	PPIL4	2	RPS20	P60866	TAGLN2	P37802
XRCC5	P13010	FUBP3	Q96I24	KPNB1	Q14974	PRDX1	Q06830	RPS21	P63220	TCOF1	Q13428
XRN2	Q9H0D6	G3BP1	Q13283	LARP1	Q6PKG0	PRPF4B	Q13523	RPS23	P62266	TCP1	P17987
YBX1	P67809	G3BP2	Q9UN86-2	LMNB1	P20700	PTBP1	P26599	RPS24	P62847	THRAP3	1
YBX3	P16989-2	GAPDH	P04406	LRRC47	Q8N1G4	RAB11FIP1	4	RPS25	P62851	TRA2B	P62995
YWHAB	P31946-2	GNB1L	Q9BYB4	LRRC59	Q96AG4	RAN	P62826	RPS26	P62854	TRIM28	Q13263
YWHAE	P62258	ZC3HAV1	Q7Z2W4	ZFR	Q96KR1	ZNF326	Q5BKZ1	ZNF706	Q9Y5V0		

Table S6. Proteins displaying significant differential interactions

Gene Name	Protein IDs	mutant_vs_control_log 2 fold change	mutant_vs_con trol_p.val	mutant_vs_co ntrol_significa nt	
ACIN1	Q9UKV3	2.68	0.0014	TRUE	Apoptotic chromatin condensation inducer in the nucleus
AKT1S1	Q96B36	3.87	2.56E-05	TRUE	Proline-rich AKT1 substrate 1
CD2AP	Q9Y5K6	3.08	0.000245	TRUE	CD2-associated protein
CKAP5	Q14008	2.18	0.0013	TRUE	Cytoskeleton-associated protein 5
CORO1B	Q9BR76	4.76	0.000167	TRUE	Coronin-1B
COX6B1	P14854	5.5	3.51E-06	TRUE	Cytochrome c oxidase subunit 6B1
CSNK2B	P67870	-2.82	0.000532	TRUE	Casein kinase II subunit beta
CTNND1	O60716	2.3	0.000923	TRUE	Catenin delta-1
DPYSL5	Q9BPU6	3.8	0.000207	TRUE	Dihydropyrimidinase-related protein 5
ELAC2	Q9BQ52	2.61	0.000164	TRUE	Zinc phosphodiesterase ELAC protein 2
GCN1L1	Q92616	2.76	0.00025	TRUE	Translational activator GCN1
HN1	Q9UK76	1.76	0.00123	TRUE	Hematological and neurological expressed 1 protein
KRT18	P05783	2.63	0.000766	TRUE	Keratin, type I cytoskeletal 18
MCMBP	Q9BTE3	1.88	0.00116	TRUE	Mini-chromosome maintenance complex-binding protein
MRPL40	Q9NQ50	2.92	0.0016	TRUE	39S ribosomal protein L40, mitochondrial
MRPS36	P82909	4.31	0.00034	TRUE	28S ribosomal protein S36, mitochondrial
MSH6	P52701	3.63	0.000413	TRUE	DNA mismatch repair protein Msh6
NUP153	P49790	2.27	0.000366	TRUE	Nuclear pore complex protein Nup153
PALLD	Q8WX93	2.94	0.000289	TRUE	Palladin
PAWR	Q96IZ0	2.58	0.00031	TRUE	PRKC apoptosis WT1 regulator protein
PIN1	Q13526	3.71	0.00102	TRUE	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1

PNPO	Q9NVS9	3.13	0.00111	TRUE	Pyridoxine-5-phosphate oxidase
PPP1R14B	Q96C90	3.61	0.000247	TRUE	Protein phosphatase 1 regulatory subunit 14B
PPP1R14C	Q8TAE6	2.74	0.000809	TRUE	Protein phosphatase 1 regulatory subunit 14C
PRPF19	Q9UMS4	-1.89	0.000803	TRUE	Pre-mRNA-processing factor 19
PRRC2C	E7EPN9	1.76	0.00119	TRUE	Protein PRRC2C
PTMS	P20962	4.09	0.000322	TRUE	Parathymosin
RANGAP1	P46060	2.39	0.00113	TRUE	Ran GTPase-activating protein 1
RBM10	P98175	2.41	0.00211	TRUE	RNA-binding protein 10
STMN1	P16949	2.03	0.000652	TRUE	Stathmin
TMA16	Q96EY4	-3.23	0.000435	TRUE	Translation machinery-associated protein 16
TOP1	P11387	-3.46	0.000197	TRUE	DNA topoisomerase 1
TOR1AIP1	Q5JTV8-3	2.46	0.000327	TRUE	Torsin-1A-interacting protein 1
YARS2	Q9Y2Z4	3.17	0.000165	TRUE	Tyrosine--tRNA ligase, mitochondrial;Tyrosine--tRNA ligase
ZC3H4	Q9UPT8	3.64	0.000483	TRUE	Zinc finger CCCH domain-containing protein 4
NUP98	P52948	1.49	0.00712	TRUE	Nuclear pore complex protein Nup98-Nup96;Nuclear pore complex protein Nup98;Nuclear pore complex protein Nup96
ATP6V1B2	P21281	1.87	0.00453	TRUE	V-type proton ATPase subunit B, brain isoform
ZRANB2	O95218	2.97	0.00258	TRUE	Zinc finger Ran-binding domain-containing protein 2
VIM	P08670	1.7	0.00279	TRUE	Vimentin
TXLNG	Q9NUQ3	2.69	0.00396	TRUE	Gamma-taxilin
SYVN1	Q86TM6	1.46	0.00976	TRUE	E3 ubiquitin-protein ligase synoviolin
SNIP1	Q8TAD8	-2.66	0.00396	TRUE	Smad nuclear-interacting protein 1
OGFR	Q9NZT2	1.55	0.00719	TRUE	Opioid growth factor receptor
MCM2	P49736	1.52	0.00511	TRUE	DNA replication licensing factor MCM2
DDX23	Q9BUQ8	1.49	0.00124	TRUE	Probable ATP-dependent RNA helicase DDX23
EPB41	P11171	1.62	0.00538	TRUE	Protein 4.1

HNRNPA1	P09651	1.59	0.00319	TRUE	Heterogeneous nuclear ribonucleoprotein A1;Heterogeneous nuclear ribonucleoprotein A1, N-terminally processed
GLUL	P15104	2.8	0.00715	TRUE	Glutamine synthetase
GNL1	P36915	2.33	0.00459	TRUE	Guanine nucleotide-binding protein-like 1

Table S7. Phosphorylation

				Intensity of phosphorylation					
Protein Name	phospho site	Localization prob	N mutant (Rep1)	N mutant (Rep2)	N mutant (Rep3)	N control (Rep1)	N control (Rep2)	N control (Rep3)	
Nucleo-capsid (N)	S206	0.994527	207590000	13224000	2966400	0	0	0	
Nucleo-capsid (N)	S2	1	955740	1907100	2265000	1921900	2763700	3502800	
Nucleo-capsid (N)	S79	0.969512	1327000	1562200	2342900	2651100	2688800	2985200	
Nucleo-capsid (N)	S180	0.997001	28745000	41617000	50307000	35401000	43784000	47220000	
Nucleo-capsid (N)	S176	0.9764	15311000	11139000	12863000	13966000	18277000	18382000	

Log2 of Intensities (related to Figure 4G)						
	N-mutant			N-control		
S206-ph	27.6291617	23.6566553	21.5002817	NA	NA	NA
S2-ph	19.8662587	20.8629491	21.1110796	20.8741018	21.3981696	21.7400772
S79-ph	20.3397369	20.5751477	21.1598639	21.3381597	21.358531	21.5093962
S180-ph	24.7768077	25.3106696	25.5842558	25.0772868	25.3839004	25.4928947
S176-ph	23.8680652	23.4091164	23.6167238	23.7354155	24.1235259	24.1317904

Table S8. Differentially expressed genes

logFC		logFC					
(N-mutant)	(N-control)	logCPM	LR	PValue	adj.P.Val	Symbols	Name
6.5909	5.7375	5.548	569.36	2.32E-124	9.22E-121	IFI44	interferon induced protein 44
4.7401	3.9182	6.2177	499.18	4.01E-109	9.13E-106	IFITM1	interferon induced transmembrane protein 1
4.5185	3.8033	6.1309	710.47	5.28E-155	2.81E-151	IFI44L	interferon induced protein 44 like
4.4642	3.5178	6.8124	439.92	2.96E-96	5.25E-93	IFIT3	interferon induced protein with tetratricopeptide repeats 3
4.2358	3.4523	7.2185	847.95	7.42E-185	1.18E-180	IFI6	interferon alpha inducible protein 6
4.0804	3.3747	6.3073	756.23	6.11E-165	4.87E-161	BST2	bone marrow stromal cell antigen 2
3.9799	3.1183	4.7279	228.02	3.07E-50	2.33E-47	RSAD2	radical S-adenosyl methionine domain containing 2
3.9792	2.9881	3.5638	123.98	1.20E-27	6.81E-25	OAS1	2'-5'-oligoadenylate synthetase 1
3.9121	3.1594	6.5215	347.03	4.41E-76	5.02E-73	IFIT2	interferon induced protein with tetratricopeptide repeats 2
3.8331	3.0151	8.0227	516.7	6.31E-113	1.68E-109	IFIT1	interferon induced protein with tetratricopeptide repeats 1
3.7219	2.9716	6.2972	431.3	2.21E-94	3.52E-91	ISG15	ISG15 ubiquitin like modifier
3.1787	2.7725	1.3727	20.032	4.47E-05	0.0036888	CXCL10	C-X-C motif chemokine ligand 10
3.0411	2.3176	7.3672	408.78	1.71E-89	2.27E-86	OAS3	2'-5'-oligoadenylate synthetase 3
2.7304	1.526	4.3908	36.542	1.16E-08	2.37E-06	PARP10	poly(ADP-ribose) polymerase family member 10
2.6618	2.2041	6.6264	549.98	3.74E-120	1.19E-116	DDX60	DExD/H-box helicase 60
2.5985	-1.0584	0.74694	22.054	1.63E-05	0.0015893	RPL37P6	ribosomal protein L37 pseudogene 6
2.5804	1.7983	4.6689	221.45	8.19E-49	5.93E-46	CMPK2	cytidine/uridine monophosphate kinase 2
2.5427	1.9862	8.1562	484.13	7.45E-106	1.48E-102	DDX58	DExD/H-box helicase 58
2.5298	2.5444	2.3412	24.707	4.31E-06	0.00051599	HSD17B13	hydroxysteroid 17-beta dehydrogenase 13
2.4544	1.7193	6.6465	243.69	1.21E-53	1.01E-50	IFITM3	interferon induced transmembrane protein 3
2.3399	1.917	1.698	17.42	0.00016493	0.011042	SP140	SP140 nuclear body protein
2.3349	1.7178	6.5483	235	9.34E-52	7.44E-49	HELZ2	helicase with zinc finger 2
2.2868	1.9946	4.0167	82.703	1.10E-18	4.74E-16	SAMD9L	sterile alpha motif domain containing 9 like
2.2536	1.4984	3.3321	65.422	6.22E-15	2.11E-12	EPSTI1	epithelial stromal interaction 1
2.2083	1.727	4.2706	121.15	4.93E-27	2.62E-24	OASL	2'-5'-oligoadenylate synthetase like

2.1724	1.6504	4.8791	188.59	1.12E-41	7.41E-39	IFIH1	interferon induced with helicase C domain 1	
2.1156	1.6829	6.6982	376.9	1.44E-82	1.76E-79	STAT1	signal transducer and activator of transcription 1	
2.04	1.581	8.7036	427.94	1.19E-93	1.72E-90	DTX3L	deltex E3 ubiquitin ligase 3L	
2.0071	1.6722	5.909	298.29	1.69E-65	1.68E-62	PLSCR1	phospholipid scramblase 1	
					ZNF625-ZN			
2.0001	1.9709	4.1073	47.297	5.37E-11	1.45E-08	F20	ZNF625-ZNF20 readthrough (NMD candidate)	
1.905	1.6937	3.5908	65.531	5.89E-15	2.04E-12	IRF9	interferon regulatory factor 9	
1.9005	1.6755	2.7615	22.49	1.31E-05	0.0013267	GBP1	guanylate binding protein 1	
1.8816	1.2956	9.0956	296.13	4.96E-65	4.65E-62	IFIT5	interferon induced protein with tetratricopeptide repeats 5	
1.8438	2.6727	2.1521	23.024	1.00E-05	0.0010654	GRIP2	glutamate receptor interacting protein 2	
1.8249	1.3301	1.9432	14.442	0.00073102	0.036745	PLSCR2	phospholipid scramblase 2	
1.8017	1.4185	7.6401	317.26	1.28E-69	1.36E-66	SAMD9	sterile alpha motif domain containing 9	
							HECT and RLD domain containing E3 ubiquitin protein	
1.7724	1.3604	5.3408	187.27	2.16E-41	1.38E-38	HERC6	ligase family member 6	
1.7705	1.3244	4.4859	71.418	3.10E-16	1.24E-13	UBE2L6	ubiquitin conjugating enzyme E2 L6	
1.7036	1.3829	6.7467	265.36	2.38E-58	2.11E-55	PARP9	poly(ADP-ribose) polymerase family member 9	
1.6596	1.0636	4.7397	119.26	1.27E-26	6.53E-24	TRIM22	tripartite motif containing 22	
1.6537	1.2988	4.069	58.028	2.51E-13	7.99E-11	SP110	SP110 nuclear body protein	
1.6507	-0.1502	2.5445	37.187	8.41E-09	1.86E-06	MYLK4	myosin light chain kinase family member 4	
1.6461	1.1795	3.2144	35.346	2.11E-08	4.26E-06	UBA7	ubiquitin like modifier activating enzyme 7	
					ARL14EPP			
1.6313	1.5866	4.433	89.156	4.37E-20	2.11E-17	1	ARL14EP pseudogene 1	
1.6292	1.2168	4.7705	106.56	7.26E-24	3.61E-21	PARP12	poly(ADP-ribose) polymerase family member 12	
1.5802	1.6322	2.9138	26.263	1.98E-06	0.00026104	RAB1AP1	RAB1A pseudogene 1	
1.5745	1.12	3.1564	29.581	3.77E-07	6.07E-05	IFI27	interferon alpha inducible protein 27	
1.5516	1.6406	2.8207	27.474	1.08E-06	0.00015811	CYP2J2	cytochrome P450 family 2 subfamily J member 2	
1.5515	0.97201	3.5967	32.437	9.05E-08	1.70E-05	SYT5	synaptotagmin 5	
1.5146	1.5784	2.4415	19.426	6.05E-05	0.0048674	REC8	REC8 meiotic recombination protein	
1.4569	1.0543	7.1461	146.05	1.93E-32	1.14E-29	USP18	ubiquitin specific peptidase 18	
1.4401	2.2006	5.1219	27.256	1.21E-06	0.00016817	ELFN2	extracellular leucine rich repeat and fibronectin type III	

domain containing 2							
1.3902	0.82668	3.3307	18.779	8.36E-05	0.0064027	ACE2	angiotensin I converting enzyme 2
1.36	1.295	5.3129	44.627	2.04E-10	5.24E-08	CXCL8	C-X-C motif chemokine ligand 8
1.3078	1.1937	6.9007	37.632	6.74E-09	1.51E-06	H2AC6	H2A clustered histone 6
1.2603	0.48038	3.8104	31.406	1.51E-07	2.74E-05	IFI16	interferon gamma inducible protein 16
1.2502	0.87272	8.3571	174.23	1.47E-38	8.98E-36	PARP14	poly(ADP-ribose) polymerase family member 14
1.244	1.1707	3.3145	14.832	0.00060168	0.032064	OR51E2	olfactory receptor family 51 subfamily E member 2
1.1763	0.97392	8.696	200.82	2.47E-44	1.71E-41	EIF2AK2	eukaryotic translation initiation factor 2 alpha kinase 2
1.1332	-0.45046	3.552	34.224	3.70E-08	7.28E-06	FBXL15	F-box and leucine rich repeat protein 15
1.0949	0.79509	4.6993	22.026	1.65E-05	0.0015981	SLC6A6	solute carrier family 6 member 6
1.0592	0.68795	4.8391	60.561	7.07E-14	2.35E-11	DDX60L	DExD/H-box 60 like
1.0586	-3.9904	4.6686	66.5	3.63E-15	1.34E-12	FKBPL	FKBP prolyl isomerase like
1.0167	0.61158	3.7267	14.183	0.00083222	0.040552	IFI35	interferon induced protein 35
0.8698	1.1839	3.6252	25.709	2.61E-06	0.00033872	KREMEN2	kringle containing transmembrane protein 2
0.85614	1.3047	3.7445	37.045	9.03E-09	1.97E-06	INHBA	inhibin subunit beta A
0.60454	-1.2691	1.9918	14.734	0.0006317	0.03311	RSPH10B2	radial spoke head 10 homolog B2
0.40296	1.4471	2.4986	21.083	2.64E-05	0.002351	FPR3	formyl peptide receptor 3
0.32437	1.6498	1.6979	14.74	0.00062979	0.03311	PDE2A	phosphodiesterase 2A
0.2971	-1.3841	4.5746	24.477	4.84E-06	0.00056699	CXCR5	C-X-C motif chemokine receptor 5
0.0016387	-1.035	3.9289	28.453	6.63E-07	9.96E-05	RIPPLY3	ripply transcriptional repressor 3
-0.151	-1.6464	2.5644	23.457	8.06E-06	0.00088573	TMPRSS13	transmembrane serine protease 13
-0.29246	-1.5043	2.9939	27.77	9.33E-07	0.00013766	HSPA12B	heat shock protein family A (Hsp70) member 12B
							olfactory receptor family 2 subfamily W member 6
-0.39018	-3.2416	0.8389	14.735	0.00063135	0.03311	OR2W6P	pseudogene
-0.9212	1.0481	2.4626	19.105	7.10E-05	0.005575	LHX6	LIM homeobox 6
-1.1054	-0.18711	3.2197	16.383	0.00027703	0.017176	CLDN2	claudin 2
ANKRD30B							
-1.1267	-1.4016	9.0029	27.408	1.12E-06	0.00015905	L	ankyrin repeat domain 30B like
-1.1349	0.20722	2.518	14.474	0.00071936	0.036273	LMO1	LIM domain only 1
-1.1446	-0.94771	3.9669	15.525	0.00042541	0.024037	SRGAP2D	SLIT-ROBO Rho GTPase activating protein 2D

							(pseudogene)
SPECC1L-A							
-1.1891	-0.0015398	4.5206	26.38	1.87E-06	0.0002503	DORA2A	SPECC1L-ADORA2A readthrough (NMD candidate)
FMC1-LUC							
-1.2704	-1.8716	4.1256	23.855	6.61E-06	0.00073607	7L2	FMC1-LUC7L2 readthrough
-1.2848	-0.88484	6.7341	88.673	5.56E-20	2.60E-17	H3P6	H3 histone pseudogene 6
-1.3599	-2.2103	1.006	13.752	0.0010321	0.047947	ADAD2	adenosine deaminase domain containing 2
apolipoprotein B mRNA editing enzyme catalytic subunit							
-1.3833	0.077091	2.9318	27.335	1.16E-06	0.00016354	APOBEC3D	3D
-1.4217	-1.0934	2.3448	18.119	0.0001163	0.0085002	CYP26C1	cytochrome P450 family 26 subfamily C member 1
-1.5358	-0.17689	3.15	24.833	4.05E-06	0.00048905	TMEM272	transmembrane protein 272
-1.6351	1.1156	1.6829	16.453	0.00026747	0.016648	IRX4	iroquois homeobox 4
-1.6583	0.058962	1.7474	14.75	0.00062658	0.03311	CST7	cystatin F
-1.7152	0.27984	3.449	29.492	3.94E-07	6.28E-05	PCDHGC5	"protocadherin gamma subfamily C, 5"
-1.7881	-1.9206	1.4148	17.614	0.0001497	0.01034	SERBP1P5	SERPINE1 mRNA binding protein 1 pseudogene 5
-2.0378	-1.1984	3.0617	20.799	3.04E-05	0.0026221	RPS28P7	ribosomal protein S28 pseudogene 7
-2.0497	0.1407	2.3942	25.451	2.97E-06	0.0003732	MYRIP	myosin VIIA and Rab interacting protein
-2.1033	-0.17562	3.7323	14.523	0.0007022	0.035633	CCBE1	collagen and calcium binding EGF domains 1
-2.1153	-0.8227	1.6676	17.81	0.00013569	0.0097389	ANO4	anoctamin 4
RPL36A-HN							
-2.2277	-1.4625	4.3468	27.063	1.33E-06	0.0001825	RNPH2	RPL36A-HNRNPH2 readthrough
eukaryotic translation initiation factor 3 subunit F							
-2.2726	-1.7089	1.6856	16.46	0.00026653	0.016648	EIF3FP3	pseudogene 3
-2.2829	-1.1793	1.7004	21.808	1.84E-05	0.001733	CLDN23	claudin 23
-3.8726	-1.8859	1.7013	35.035	2.47E-08	4.92E-06	FRG2C	FSHD region gene 2 family member C

Table S9. Primers**Primers used for cloning**

Primer Name	Sequence 5' to 3'
pLVX-N1-F1	CTATTCCGGTGAATTCGCCG
pLVX-N1-R1	GGGGCGGGATCCTTACTTTTC
pLVX-N1-Mut-F1	CCAGGGTCCAGTAAACGAACAAAGTCCGGCGC
pLVX-N1-Mut-R1	GCGCCGGACTTGTTCGTTACTGGACCCTGG

2019-nCoV CDC Primers and Probe

Name	Catalog#
nCOV_N1 Forward Primer Aliquot, 50 nmol	10006821
nCOV_N1 Reverse Primer Aliquot, 50 nmol	10006822
nCOV_N1 Probe Aliquot, 25 nmol	10006823
nCOV_N2 Forward Primer Aliquot, 50 nmol	10006824
nCOV_N2 Reverse Primer Aliquot, 50 nmol	10006825
nCOV_N2 Probe Aliquot, 25 nmol	10006826
E gene E_Sarbeco_F	ACAGGTACGTTAATAGTTAATAGCGT
E_Sarbeco_R	ATATTGCAGCAGTACGCACACA
E_Sarbeco_P1	FAM-ACACTAGCCATCCTTACTGCGCTTCG-BBQ

References

- 1 Algaissi, A. A., Alharbi, N. K., Hassanain, M. & Hashem, A. M. Preparedness and response to COVID-19 in Saudi Arabia: Building on MERS experience. *J Infect Public Health* **13**, 834-838, doi:10.1016/j.jiph.2020.04.016 (2020).
- 2 Li, H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. *Bioinformatics* **27**, 2987-2993, doi:10.1093/bioinformatics/btr509 (2011).
- 3 Korber, B. *et al.* Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell* **182**, 812-827 e819, doi:10.1016/j.cell.2020.06.043 (2020).
- 4 Lorenzo-Redondo, R. *et al.* A Unique Clade of SARS-CoV-2 Viruses is Associated with Lower Viral Loads in Patient Upper Airways. *medRxiv*, 2020.2005.2019.20107144, doi:10.1101/2020.05.19.20107144 (2020).
- 5 Volz, E. *et al.* Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. *Cell* **184**, 64-75 e11, doi:10.1016/j.cell.2020.11.020 (2021).
- 6 Barbu, M. G., Thompson, R. J., Thompson, D. C., Cretoiu, D. & Suciu, N. The Impact of SARS-CoV-2 on the Most Common Comorbidities-A Retrospective Study on 814 COVID-19 Deaths in Romania. *Front Med (Lausanne)* **7**, 567199, doi:10.3389/fmed.2020.567199 (2020).
- 7 Reilev, M. *et al.* Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. *Int J Epidemiol* **49**, 1468-1481, doi:10.1093/ije/dyaa140 (2020).
- 8 Yang, J. *et al.* Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis* **94**, 91-95, doi:10.1016/j.ijid.2020.03.017 (2020).
- 9 Espinosa, O. A. *et al.* Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis. *Rev Inst Med*

- Trop Sao Paulo* **62**, e43, doi:10.1590/S1678-9946202062043 (2020).
- 10 Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054-1062, doi:10.1016/S0140-6736(20)30566-3 (2020).
- 11 Pantea Stoian, A. *et al.* Death by SARS-CoV 2: a Romanian COVID-19 multi-centre comorbidity study. *Scientific reports* **10**, 21613, doi:10.1038/s41598-020-78575-w (2020).
- 12 Li, B. *et al.* Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clin Res Cardiol* **109**, 531-538, doi:10.1007/s00392-020-01626-9 (2020).